TW202333803A - 用於肺癌之治療性ｒｎａ（一） - Google Patents

Info

Publication number

TW202333803A

TW202333803A TW111138246A TW111138246A TW202333803A TW 202333803 A TW202333803 A TW 202333803A TW 111138246 A TW111138246 A TW 111138246A TW 111138246 A TW111138246 A TW 111138246A TW 202333803 A TW202333803 A TW 202333803A

Authority

TW

Taiwan

Prior art keywords

amino acid

acid sequence

rna

seq

sequence

Prior art date

2021-10-11

Links

• Espacenet
• Global Dossier
• Discuss

• 208000020816 lung neoplasm Diseases 0.000 title claims abstract description 39
• 201000005202 lung cancer Diseases 0.000 title claims abstract description 33
• 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 32
• 230000001225 therapeutic effect Effects 0.000 title claims abstract description 21
• 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 645
• 239000000203 mixture Substances 0.000 claims abstract description 140
• 238000000034 method Methods 0.000 claims abstract description 86
• 238000011282 treatment Methods 0.000 claims abstract description 47
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 570
• 239000000427 antigen Substances 0.000 claims description 288
• 108091007433 antigens Proteins 0.000 claims description 285
• 102000036639 antigens Human genes 0.000 claims description 285
• 239000002773 nucleotide Substances 0.000 claims description 249
• 125000003729 nucleotide group Chemical group 0.000 claims description 247
• 230000002163 immunogen Effects 0.000 claims description 214
• 239000002245 particle Substances 0.000 claims description 129
• 239000012634 fragment Substances 0.000 claims description 113
• 108090000229 Claudin-6 Proteins 0.000 claims description 83
• 102100021533 Kita-kyushu lung cancer antigen 1 Human genes 0.000 claims description 83
• 102000003859 Claudin-6 Human genes 0.000 claims description 82
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 78
• 150000002632 lipids Chemical class 0.000 claims description 78
• 230000030741 antigen processing and presentation Effects 0.000 claims description 76
• 101710203618 Kita-kyushu lung cancer antigen 1 Proteins 0.000 claims description 75
• 201000010099 disease Diseases 0.000 claims description 71
• 238000002360 preparation method Methods 0.000 claims description 67
• 201000001441 melanoma Diseases 0.000 claims description 63
• 239000002479 lipoplex Substances 0.000 claims description 56
• 230000014509 gene expression Effects 0.000 claims description 52
• 230000006058 immune tolerance Effects 0.000 claims description 50
• 239000008194 pharmaceutical composition Substances 0.000 claims description 43
• 108091026890 Coding region Proteins 0.000 claims description 31
• 239000002502 liposome Substances 0.000 claims description 30
• 108020005345 3' Untranslated Regions Proteins 0.000 claims description 27
• 108020003589 5' Untranslated Regions Proteins 0.000 claims description 26
• 230000001965 increasing effect Effects 0.000 claims description 26
• 229960000814 tetanus toxoid Drugs 0.000 claims description 25
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 23
• 108020004705 Codon Proteins 0.000 claims description 21
• 238000001990 intravenous administration Methods 0.000 claims description 19
• 238000002347 injection Methods 0.000 claims description 15
• 239000007924 injection Substances 0.000 claims description 15
• 101710135378 pH 6 antigen Proteins 0.000 claims description 15
• 238000002156 mixing Methods 0.000 claims description 12
• 239000003085 diluting agent Substances 0.000 claims description 11
• 230000008859 change Effects 0.000 claims description 10
• 238000005457 optimization Methods 0.000 claims description 10
• 239000007788 liquid Substances 0.000 claims description 9
• 230000003449 preventive effect Effects 0.000 claims description 9
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
• 230000001086 cytosolic effect Effects 0.000 claims description 7
• 239000003937 drug carrier Substances 0.000 claims description 7
• 241000282412 Homo Species 0.000 claims description 6
• 239000007787 solid Substances 0.000 claims description 6
• 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims description 4
• 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims description 4
• 230000002265 prevention Effects 0.000 claims description 3
• 230000006057 immunotolerant effect Effects 0.000 claims 1
• 230000003614 tolerogenic effect Effects 0.000 claims 1
• 206010028980 Neoplasm Diseases 0.000 abstract description 150
• 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract description 47
• 201000011510 cancer Diseases 0.000 abstract description 44
• 102000040650 (ribonucleotides)n+m Human genes 0.000 abstract description 18
• 206010027476 Metastases Diseases 0.000 abstract description 13
• 230000009401 metastasis Effects 0.000 abstract description 7
• 230000036210 malignancy Effects 0.000 abstract description 6
• 230000004083 survival effect Effects 0.000 abstract description 4
• 208000037821 progressive disease Diseases 0.000 abstract description 2
• 108090000765 processed proteins & peptides Proteins 0.000 description 121
• 150000001413 amino acids Chemical class 0.000 description 95
• 229960005486 vaccine Drugs 0.000 description 93
• 108090000623 proteins and genes Proteins 0.000 description 90
• 235000001014 amino acid Nutrition 0.000 description 81
• 229940024606 amino acid Drugs 0.000 description 79
• 210000001744 T-lymphocyte Anatomy 0.000 description 76
• 102000004169 proteins and genes Human genes 0.000 description 71
• 235000018102 proteins Nutrition 0.000 description 69
• 210000004027 cell Anatomy 0.000 description 65
• -1 cationic lipid Chemical class 0.000 description 47
• 210000001519 tissue Anatomy 0.000 description 46
• DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 44
• 210000000612 antigen-presenting cell Anatomy 0.000 description 44
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 44
• 230000028993 immune response Effects 0.000 description 43
• 102000004196 processed proteins & peptides Human genes 0.000 description 37
• 238000004458 analytical method Methods 0.000 description 31
• 101001036406 Homo sapiens Melanoma-associated antigen C1 Proteins 0.000 description 30
• 102100039447 Melanoma-associated antigen C1 Human genes 0.000 description 30
• 238000011529 RT qPCR Methods 0.000 description 29
• UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 description 27
• 229940045145 uridine Drugs 0.000 description 27
• 241000699670 Mus sp. Species 0.000 description 25
• 238000009472 formulation Methods 0.000 description 25
• 239000002777 nucleoside Substances 0.000 description 25
• 150000003833 nucleoside derivatives Chemical class 0.000 description 25
• 101001005719 Homo sapiens Melanoma-associated antigen 3 Proteins 0.000 description 24
• 102100025082 Melanoma-associated antigen 3 Human genes 0.000 description 24
• 241001465754 Metazoa Species 0.000 description 24
• 210000000952 spleen Anatomy 0.000 description 24
• 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 23
• 210000004443 dendritic cell Anatomy 0.000 description 23
• 238000000338 in vitro Methods 0.000 description 23
• 201000005249 lung adenocarcinoma Diseases 0.000 description 23
• 150000007523 nucleic acids Chemical class 0.000 description 23
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
• 230000000890 antigenic effect Effects 0.000 description 22
• 201000005243 lung squamous cell carcinoma Diseases 0.000 description 22
• 108020004999 messenger RNA Proteins 0.000 description 22
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
• 101001005720 Homo sapiens Melanoma-associated antigen 4 Proteins 0.000 description 20
• 108700018351 Major Histocompatibility Complex Proteins 0.000 description 20
• 102100025077 Melanoma-associated antigen 4 Human genes 0.000 description 20
• DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 20
• 210000004988 splenocyte Anatomy 0.000 description 20
• DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 20
• LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 19
• 102000008096 B7-H1 Antigen Human genes 0.000 description 19
• 108010074708 B7-H1 Antigen Proteins 0.000 description 19
• 230000004044 response Effects 0.000 description 19
• 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 19
• 238000013518 transcription Methods 0.000 description 19
• 230000035897 transcription Effects 0.000 description 19
• 239000013641 positive control Substances 0.000 description 17
• 239000000523 sample Substances 0.000 description 17
• 238000012360 testing method Methods 0.000 description 17
• 230000006698 induction Effects 0.000 description 16
• 238000002255 vaccination Methods 0.000 description 16
• 210000002540 macrophage Anatomy 0.000 description 15
• 102000039446 nucleic acids Human genes 0.000 description 15
• 108020004707 nucleic acids Proteins 0.000 description 15
• 108010074328 Interferon-gamma Proteins 0.000 description 14
• 238000003556 assay Methods 0.000 description 14
• 239000000463 material Substances 0.000 description 14
• 239000000047 product Substances 0.000 description 14
• 239000000243 solution Substances 0.000 description 14
• 102100037850 Interferon gamma Human genes 0.000 description 13
• 102000043129 MHC class I family Human genes 0.000 description 13
• 108091054437 MHC class I family Proteins 0.000 description 13
• 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 13
• 230000006870 function Effects 0.000 description 13
• 230000005847 immunogenicity Effects 0.000 description 13
• 201000003445 large cell neuroendocrine carcinoma Diseases 0.000 description 13
• 241000894007 species Species 0.000 description 13
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 12
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 12
• 108020004414 DNA Proteins 0.000 description 12
• 230000005867 T cell response Effects 0.000 description 12
• 230000001939 inductive effect Effects 0.000 description 12
• DWRXFEITVBNRMK-JXOAFFINSA-N ribothymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JXOAFFINSA-N 0.000 description 12
• 150000003839 salts Chemical class 0.000 description 12
• 210000001550 testis Anatomy 0.000 description 12
• 238000013519 translation Methods 0.000 description 12
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
• 108700026244 Open Reading Frames Proteins 0.000 description 11
• 229930185560 Pseudouridine Natural products 0.000 description 11
• PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 description 11
• WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 description 11
• PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 description 11
• 241000699666 Mus <mouse, genus> Species 0.000 description 10
• 239000002671 adjuvant Substances 0.000 description 10
• 239000003814 drug Substances 0.000 description 10
• 230000000694 effects Effects 0.000 description 10
• 230000001394 metastastic effect Effects 0.000 description 10
• 206010061289 metastatic neoplasm Diseases 0.000 description 10
• 230000008569 process Effects 0.000 description 10
• 239000011780 sodium chloride Substances 0.000 description 10
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 9
• 102000043131 MHC class II family Human genes 0.000 description 9
• 108091054438 MHC class II family Proteins 0.000 description 9
• 239000000872 buffer Substances 0.000 description 9
• 238000010804 cDNA synthesis Methods 0.000 description 9
• 238000004422 calculation algorithm Methods 0.000 description 9
• 230000001186 cumulative effect Effects 0.000 description 9
• 238000002474 experimental method Methods 0.000 description 9
• 230000004927 fusion Effects 0.000 description 9
• 230000004048 modification Effects 0.000 description 9
• 238000012986 modification Methods 0.000 description 9
• 125000003835 nucleoside group Chemical group 0.000 description 9
• 230000037452 priming Effects 0.000 description 9
• 239000000126 substance Substances 0.000 description 9
• 238000012546 transfer Methods 0.000 description 9
• 108020004635 Complementary DNA Proteins 0.000 description 8
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
• 238000009825 accumulation Methods 0.000 description 8
• 125000002091 cationic group Chemical group 0.000 description 8
• 239000002738 chelating agent Substances 0.000 description 8
• 239000002299 complementary DNA Substances 0.000 description 8
• 230000002708 enhancing effect Effects 0.000 description 8
• 238000001727 in vivo Methods 0.000 description 8
• 150000002500 ions Chemical class 0.000 description 8
• 239000013642 negative control Substances 0.000 description 8
• 229920001184 polypeptide Polymers 0.000 description 8
• 239000003381 stabilizer Substances 0.000 description 8
• 230000004936 stimulating effect Effects 0.000 description 8
• 238000002560 therapeutic procedure Methods 0.000 description 8
• NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 7
• 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 description 7
• 238000003559 RNA-seq method Methods 0.000 description 7
• 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 description 7
• 206010043376 Tetanus Diseases 0.000 description 7
• 230000015572 biosynthetic process Effects 0.000 description 7
• 239000003795 chemical substances by application Substances 0.000 description 7
• 150000001875 compounds Chemical class 0.000 description 7
• 238000012217 deletion Methods 0.000 description 7
• 230000037430 deletion Effects 0.000 description 7
• 229940079593 drug Drugs 0.000 description 7
• 208000007276 esophageal squamous cell carcinoma Diseases 0.000 description 7
• 238000010253 intravenous injection Methods 0.000 description 7
• 210000004072 lung Anatomy 0.000 description 7
• 210000000056 organ Anatomy 0.000 description 7
• 230000002441 reversible effect Effects 0.000 description 7
• 230000003248 secreting effect Effects 0.000 description 7
• 238000006467 substitution reaction Methods 0.000 description 7
• 108700028369 Alleles Proteins 0.000 description 6
• 239000012269 PD-1/PD-L1 inhibitor Substances 0.000 description 6
• 108010029485 Protein Isoforms Proteins 0.000 description 6
• 102000001708 Protein Isoforms Human genes 0.000 description 6
• ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 6
• 239000002253 acid Substances 0.000 description 6
• 239000004480 active ingredient Substances 0.000 description 6
• OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine group Chemical group [C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(N)=NC=NC12 OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 6
• 239000008346 aqueous phase Substances 0.000 description 6
• 210000003719 b-lymphocyte Anatomy 0.000 description 6
• 210000004556 brain Anatomy 0.000 description 6
• 230000015556 catabolic process Effects 0.000 description 6
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
• 238000003780 insertion Methods 0.000 description 6
• 230000037431 insertion Effects 0.000 description 6
• 208000037841 lung tumor Diseases 0.000 description 6
• 239000002609 medium Substances 0.000 description 6
• 229940121653 pd-1/pd-l1 inhibitor Drugs 0.000 description 6
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
• 230000009467 reduction Effects 0.000 description 6
• 206010041823 squamous cell carcinoma Diseases 0.000 description 6
• 230000000638 stimulation Effects 0.000 description 6
• 208000024891 symptom Diseases 0.000 description 6
• 238000007910 systemic administration Methods 0.000 description 6
• 210000004881 tumor cell Anatomy 0.000 description 6
• 239000013598 vector Substances 0.000 description 6
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 5
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 5
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
• 101000971605 Homo sapiens Kita-kyushu lung cancer antigen 1 Proteins 0.000 description 5
• 108091036407 Polyadenylation Proteins 0.000 description 5
• 238000013459 approach Methods 0.000 description 5
• 210000000805 cytoplasm Anatomy 0.000 description 5
• 238000006731 degradation reaction Methods 0.000 description 5
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
• 208000035475 disorder Diseases 0.000 description 5
• 210000002472 endoplasmic reticulum Anatomy 0.000 description 5
• 230000001900 immune effect Effects 0.000 description 5
• 210000004698 lymphocyte Anatomy 0.000 description 5
• 238000004519 manufacturing process Methods 0.000 description 5
• 239000011859 microparticle Substances 0.000 description 5
• 239000002953 phosphate buffered saline Substances 0.000 description 5
• 238000011518 platinum-based chemotherapy Methods 0.000 description 5
• 235000004400 serine Nutrition 0.000 description 5
• 238000009097 single-agent therapy Methods 0.000 description 5
• 230000003393 splenic effect Effects 0.000 description 5
• 230000009885 systemic effect Effects 0.000 description 5
• ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 4
• ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 4
• 208000003174 Brain Neoplasms Diseases 0.000 description 4
• 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 4
• 102000004190 Enzymes Human genes 0.000 description 4
• 108090000790 Enzymes Proteins 0.000 description 4
• 239000004471 Glycine Substances 0.000 description 4
• 239000007995 HEPES buffer Substances 0.000 description 4
• 108010075326 HLA-B51 Antigen Proteins 0.000 description 4
• 241000701024 Human betaherpesvirus 5 Species 0.000 description 4
• 108010063738 Interleukins Proteins 0.000 description 4
• 102000015696 Interleukins Human genes 0.000 description 4
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
• 206010059282 Metastases to central nervous system Diseases 0.000 description 4
• 206010027468 Metastases to spine Diseases 0.000 description 4
• 108091034057 RNA (poly(A)) Proteins 0.000 description 4
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
• 108091023045 Untranslated Region Proteins 0.000 description 4
• 238000007792 addition Methods 0.000 description 4
• 125000003277 amino group Chemical group 0.000 description 4
• 230000001413 cellular effect Effects 0.000 description 4
• 238000006243 chemical reaction Methods 0.000 description 4
• 239000003153 chemical reaction reagent Substances 0.000 description 4
• UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 4
• OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
• 239000006185 dispersion Substances 0.000 description 4
• 238000002296 dynamic light scattering Methods 0.000 description 4
• 238000005516 engineering process Methods 0.000 description 4
• 230000001747 exhibiting effect Effects 0.000 description 4
• 238000007710 freezing Methods 0.000 description 4
• 230000008014 freezing Effects 0.000 description 4
• 108020001507 fusion proteins Proteins 0.000 description 4
• 102000037865 fusion proteins Human genes 0.000 description 4
• 102000054766 genetic haplotypes Human genes 0.000 description 4
• 230000036541 health Effects 0.000 description 4
• 210000000987 immune system Anatomy 0.000 description 4
• 230000003053 immunization Effects 0.000 description 4
• 238000009169 immunotherapy Methods 0.000 description 4
• 229940047122 interleukins Drugs 0.000 description 4
• 238000007726 management method Methods 0.000 description 4
• 239000002105 nanoparticle Substances 0.000 description 4
• 244000052769 pathogen Species 0.000 description 4
• SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
• 238000012545 processing Methods 0.000 description 4
• 230000000069 prophylactic effect Effects 0.000 description 4
• 210000004989 spleen cell Anatomy 0.000 description 4
• 238000003860 storage Methods 0.000 description 4
• 230000008685 targeting Effects 0.000 description 4
• 230000005945 translocation Effects 0.000 description 4
• 230000032258 transport Effects 0.000 description 4
• 230000004614 tumor growth Effects 0.000 description 4
• 238000011144 upstream manufacturing Methods 0.000 description 4
• SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 3
• UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 3
• 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 3
• 108091033380 Coding strand Proteins 0.000 description 3
• MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 3
• UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 3
• NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 3
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
• 238000011510 Elispot assay Methods 0.000 description 3
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
• 101000896557 Homo sapiens Eukaryotic translation initiation factor 3 subunit B Proteins 0.000 description 3
• 101000988834 Homo sapiens Hypoxanthine-guanine phosphoribosyltransferase Proteins 0.000 description 3
• 108090000144 Human Proteins Proteins 0.000 description 3
• 102000003839 Human Proteins Human genes 0.000 description 3
• 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 3
• 206010062016 Immunosuppression Diseases 0.000 description 3
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
• QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 3
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 3
• 206010061309 Neoplasm progression Diseases 0.000 description 3
• 102100040678 Programmed cell death protein 1 Human genes 0.000 description 3
• 101710089372 Programmed cell death protein 1 Proteins 0.000 description 3
• 229930006000 Sucrose Natural products 0.000 description 3
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
• 230000006044 T cell activation Effects 0.000 description 3
• 230000002378 acidificating effect Effects 0.000 description 3
• UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical group C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 3
• 230000002411 adverse Effects 0.000 description 3
• 150000001412 amines Chemical class 0.000 description 3
• 230000006907 apoptotic process Effects 0.000 description 3
• 235000003704 aspartic acid Nutrition 0.000 description 3
• 230000009286 beneficial effect Effects 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
• 239000006172 buffering agent Substances 0.000 description 3
• 210000004899 c-terminal region Anatomy 0.000 description 3
• 239000006285 cell suspension Substances 0.000 description 3
• 235000012000 cholesterol Nutrition 0.000 description 3
• 239000002577 cryoprotective agent Substances 0.000 description 3
• 230000034994 death Effects 0.000 description 3
• 238000001514 detection method Methods 0.000 description 3
• 238000011161 development Methods 0.000 description 3
• 230000018109 developmental process Effects 0.000 description 3
• 230000004069 differentiation Effects 0.000 description 3
• ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 3
• 238000009826 distribution Methods 0.000 description 3
• 229960003668 docetaxel Drugs 0.000 description 3
• 239000012636 effector Substances 0.000 description 3
• 235000013922 glutamic acid Nutrition 0.000 description 3
• 239000004220 glutamic acid Substances 0.000 description 3
• 229940029575 guanosine Drugs 0.000 description 3
• 210000002865 immune cell Anatomy 0.000 description 3
• 230000036039 immunity Effects 0.000 description 3
• 238000002649 immunization Methods 0.000 description 3
• 230000001506 immunosuppresive effect Effects 0.000 description 3
• 238000001802 infusion Methods 0.000 description 3
• 230000003902 lesion Effects 0.000 description 3
• 210000004185 liver Anatomy 0.000 description 3
• 239000011159 matrix material Substances 0.000 description 3
• 238000005259 measurement Methods 0.000 description 3
• 238000010172 mouse model Methods 0.000 description 3
• 230000007935 neutral effect Effects 0.000 description 3
• 210000004940 nucleus Anatomy 0.000 description 3
• 238000007911 parenteral administration Methods 0.000 description 3
• 239000012071 phase Substances 0.000 description 3
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
• 210000002826 placenta Anatomy 0.000 description 3
• 239000003755 preservative agent Substances 0.000 description 3
• 230000001681 protective effect Effects 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 125000002652 ribonucleotide group Chemical group 0.000 description 3
• 238000012216 screening Methods 0.000 description 3
• 230000028327 secretion Effects 0.000 description 3
• 239000002904 solvent Substances 0.000 description 3
• 238000001694 spray drying Methods 0.000 description 3
• 238000010186 staining Methods 0.000 description 3
• 239000005720 sucrose Substances 0.000 description 3
• 238000009121 systemic therapy Methods 0.000 description 3
• 230000002381 testicular Effects 0.000 description 3
• 231100000419 toxicity Toxicity 0.000 description 3
• 230000001988 toxicity Effects 0.000 description 3
• 230000009261 transgenic effect Effects 0.000 description 3
• 230000005751 tumor progression Effects 0.000 description 3
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
• 235000002374 tyrosine Nutrition 0.000 description 3
• 229940035893 uracil Drugs 0.000 description 3
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
• JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 description 2
• IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 2
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
• RZQXOGQSPBYUKH-UHFFFAOYSA-N 3-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound OCC(CO)(CO)NCC(O)CS(O)(=O)=O RZQXOGQSPBYUKH-UHFFFAOYSA-N 0.000 description 2
• 102100028104 39S ribosomal protein L19, mitochondrial Human genes 0.000 description 2
• VTGBLFNEDHVUQA-XUTVFYLZSA-N 4-Thio-1-methyl-pseudouridine Chemical compound S=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 VTGBLFNEDHVUQA-XUTVFYLZSA-N 0.000 description 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
• VSCNRXVDHRNJOA-PNHWDRBUSA-N 5-(carboxymethylaminomethyl)uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(CNCC(O)=O)=C1 VSCNRXVDHRNJOA-PNHWDRBUSA-N 0.000 description 2
• QXDXBKZJFLRLCM-UAKXSSHOSA-N 5-hydroxyuridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(O)=C1 QXDXBKZJFLRLCM-UAKXSSHOSA-N 0.000 description 2
• 208000030507 AIDS Diseases 0.000 description 2
• 239000004475 Arginine Substances 0.000 description 2
• 208000023275 Autoimmune disease Diseases 0.000 description 2
• 206010006187 Breast cancer Diseases 0.000 description 2
• 208000026310 Breast neoplasm Diseases 0.000 description 2
• 101150077194 CAP1 gene Proteins 0.000 description 2
• 101150034344 CT83 gene Proteins 0.000 description 2
• 201000009030 Carcinoma Diseases 0.000 description 2
• 108010012236 Chemokines Proteins 0.000 description 2
• 102000019034 Chemokines Human genes 0.000 description 2
• 102000002029 Claudin Human genes 0.000 description 2
• 108050009302 Claudin Proteins 0.000 description 2
• 241000193449 Clostridium tetani Species 0.000 description 2
• 108700010070 Codon Usage Proteins 0.000 description 2
• 208000035473 Communicable disease Diseases 0.000 description 2
• 206010062759 Congenital dyskeratosis Diseases 0.000 description 2
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
• XULFJDKZVHTRLG-JDVCJPALSA-N DOSPA trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCNC(=O)C(CCCNCCCN)NCCCN)OCCCCCCCC\C=C/CCCCCCCC XULFJDKZVHTRLG-JDVCJPALSA-N 0.000 description 2
• 206010061818 Disease progression Diseases 0.000 description 2
• 102100034893 E3 ubiquitin-protein ligase HUWE1 Human genes 0.000 description 2
• 108700039887 Essential Genes Proteins 0.000 description 2
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
• 206010015548 Euthanasia Diseases 0.000 description 2
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 2
• 101001079803 Homo sapiens 39S ribosomal protein L19, mitochondrial Proteins 0.000 description 2
• 101001019732 Homo sapiens E3 ubiquitin-protein ligase HUWE1 Proteins 0.000 description 2
• 241000725303 Human immunodeficiency virus Species 0.000 description 2
• 208000026350 Inborn Genetic disease Diseases 0.000 description 2
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
• 239000004472 Lysine Substances 0.000 description 2
• 108700036248 MT-RNR1 Proteins 0.000 description 2
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
• 241000699660 Mus musculus Species 0.000 description 2
• 101100245221 Mus musculus Prss8 gene Proteins 0.000 description 2
• UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical class CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 2
• JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 2
• SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
• 229940038430 NY-ESO-1 vaccine Drugs 0.000 description 2
• 238000012408 PCR amplification Methods 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 102100034391 Porphobilinogen deaminase Human genes 0.000 description 2
• 101710189720 Porphobilinogen deaminase Proteins 0.000 description 2
• 101710170827 Porphobilinogen deaminase, chloroplastic Proteins 0.000 description 2
• WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
• 101710100896 Probable porphobilinogen deaminase Proteins 0.000 description 2
• 108010076504 Protein Sorting Signals Proteins 0.000 description 2
• 101710156592 Putative TATA-binding protein pB263R Proteins 0.000 description 2
• 229940022005 RNA vaccine Drugs 0.000 description 2
• 241000700159 Rattus Species 0.000 description 2
• 206010039491 Sarcoma Diseases 0.000 description 2
• 206010041067 Small cell lung cancer Diseases 0.000 description 2
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
• UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
• 108091081024 Start codon Proteins 0.000 description 2
• 230000024932 T cell mediated immunity Effects 0.000 description 2
• 101710145783 TATA-box-binding protein Proteins 0.000 description 2
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
• 239000004473 Threonine Substances 0.000 description 2
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
• 108020004566 Transfer RNA Proteins 0.000 description 2
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
• PGAVKCOVUIYSFO-XVFCMESISA-N UTP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-XVFCMESISA-N 0.000 description 2
• DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 description 2
• FOGRQMPFHUHIGU-UHFFFAOYSA-N Uridylic acid Natural products OC1C(OP(O)(O)=O)C(CO)OC1N1C(=O)NC(=O)C=C1 FOGRQMPFHUHIGU-UHFFFAOYSA-N 0.000 description 2
• 208000002495 Uterine Neoplasms Diseases 0.000 description 2
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
• 241000700605 Viruses Species 0.000 description 2
• 208000027418 Wounds and injury Diseases 0.000 description 2
• 230000005856 abnormality Effects 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 230000003213 activating effect Effects 0.000 description 2
• 208000009956 adenocarcinoma Diseases 0.000 description 2
• 235000004279 alanine Nutrition 0.000 description 2
• 230000004075 alteration Effects 0.000 description 2
• 230000006229 amino acid addition Effects 0.000 description 2
• 125000000539 amino acid group Chemical group 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
• 230000001363 autoimmune Effects 0.000 description 2
• 230000004888 barrier function Effects 0.000 description 2
• 239000011324 bead Substances 0.000 description 2
• 210000004369 blood Anatomy 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• 210000001185 bone marrow Anatomy 0.000 description 2
• 238000004364 calculation method Methods 0.000 description 2
• 150000001720 carbohydrates Chemical group 0.000 description 2
• 235000014633 carbohydrates Nutrition 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 238000005266 casting Methods 0.000 description 2
• 230000010261 cell growth Effects 0.000 description 2
• 230000004663 cell proliferation Effects 0.000 description 2
• 230000007969 cellular immunity Effects 0.000 description 2
• 230000036755 cellular response Effects 0.000 description 2
• 210000003169 central nervous system Anatomy 0.000 description 2
• 229930183167 cerebroside Natural products 0.000 description 2
• RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• 230000002759 chromosomal effect Effects 0.000 description 2
• 210000000349 chromosome Anatomy 0.000 description 2
• 238000002648 combination therapy Methods 0.000 description 2
• 238000002591 computed tomography Methods 0.000 description 2
• 230000001276 controlling effect Effects 0.000 description 2
• 230000000139 costimulatory effect Effects 0.000 description 2
• 229940104302 cytosine Drugs 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• ZPTBLXKRQACLCR-XVFCMESISA-N dihydrouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)CC1 ZPTBLXKRQACLCR-XVFCMESISA-N 0.000 description 2
• OGGXGZAMXPVRFZ-UHFFFAOYSA-N dimethylarsinic acid Chemical compound C[As](C)(O)=O OGGXGZAMXPVRFZ-UHFFFAOYSA-N 0.000 description 2
• 230000005750 disease progression Effects 0.000 description 2
• BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
• 231100000371 dose-limiting toxicity Toxicity 0.000 description 2
• 230000037437 driver mutation Effects 0.000 description 2
• 230000004064 dysfunction Effects 0.000 description 2
• 208000009356 dyskeratosis congenita Diseases 0.000 description 2
• 230000009881 electrostatic interaction Effects 0.000 description 2
• 239000003623 enhancer Substances 0.000 description 2
• 210000002919 epithelial cell Anatomy 0.000 description 2
• 238000010195 expression analysis Methods 0.000 description 2
• 238000000605 extraction Methods 0.000 description 2
• 238000001125 extrusion Methods 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• 239000007850 fluorescent dye Substances 0.000 description 2
• 235000013305 food Nutrition 0.000 description 2
• 238000004108 freeze drying Methods 0.000 description 2
• 239000007789 gas Substances 0.000 description 2
• 210000001035 gastrointestinal tract Anatomy 0.000 description 2
• 208000016361 genetic disease Diseases 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• 235000011187 glycerol Nutrition 0.000 description 2
• 239000001963 growth medium Substances 0.000 description 2
• RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 2
• 235000013928 guanylic acid Nutrition 0.000 description 2
• 238000010438 heat treatment Methods 0.000 description 2
• 210000002443 helper t lymphocyte Anatomy 0.000 description 2
• 230000001024 immunotherapeutic effect Effects 0.000 description 2
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
• 229960000310 isoleucine Drugs 0.000 description 2
• JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 2
• 208000003849 large cell carcinoma Diseases 0.000 description 2
• KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
• 210000001165 lymph node Anatomy 0.000 description 2
• 108700021021 mRNA Vaccine Proteins 0.000 description 2
• 230000003211 malignant effect Effects 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 230000001404 mediated effect Effects 0.000 description 2
• 210000003071 memory t lymphocyte Anatomy 0.000 description 2
• 238000012544 monitoring process Methods 0.000 description 2
• 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
• 235000019799 monosodium phosphate Nutrition 0.000 description 2
• 230000035772 mutation Effects 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 230000003287 optical effect Effects 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 229940067082 pentetate Drugs 0.000 description 2
• 229960003330 pentetic acid Drugs 0.000 description 2
• 210000001539 phagocyte Anatomy 0.000 description 2
• 235000011056 potassium acetate Nutrition 0.000 description 2
• 230000002829 reductive effect Effects 0.000 description 2
• 238000010839 reverse transcription Methods 0.000 description 2
• 210000003705 ribosome Anatomy 0.000 description 2
• 208000000587 small cell lung carcinoma Diseases 0.000 description 2
• 239000001632 sodium acetate Substances 0.000 description 2
• 235000017281 sodium acetate Nutrition 0.000 description 2
• AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
• PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
• 210000001845 splenic macrophage Anatomy 0.000 description 2
• 239000007921 spray Substances 0.000 description 2
• 150000003431 steroids Chemical class 0.000 description 2
• CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• 235000008521 threonine Nutrition 0.000 description 2
• 210000001685 thyroid gland Anatomy 0.000 description 2
• 238000011830 transgenic mouse model Methods 0.000 description 2
• 239000001226 triphosphate Substances 0.000 description 2
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
• DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 description 2
• PGAVKCOVUIYSFO-UHFFFAOYSA-N uridine-triphosphate Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-UHFFFAOYSA-N 0.000 description 2
• 206010046766 uterine cancer Diseases 0.000 description 2
• 210000004291 uterus Anatomy 0.000 description 2
• 239000004474 valine Substances 0.000 description 2
• 238000005406 washing Methods 0.000 description 2
• 239000008215 water for injection Substances 0.000 description 2
• 230000036642 wellbeing Effects 0.000 description 2
• HDTRYLNUVZCQOY-UHFFFAOYSA-N &alpha;-D-glucopyranosyl-&alpha;-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
• LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical class OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
• OYTVCAGSWWRUII-DWJKKKFUSA-N 1-Methyl-1-deazapseudouridine Chemical compound CC1C=C(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O OYTVCAGSWWRUII-DWJKKKFUSA-N 0.000 description 1
• BDYFCYHXUPHLAY-HKUMRIAESA-N 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-[(3-methylbut-2-enylamino)methyl]pyrimidine-2,4-dione Chemical compound CC(C)=CCNCc1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]c1=O BDYFCYHXUPHLAY-HKUMRIAESA-N 0.000 description 1
• OTFGHFBGGZEXEU-PEBGCTIMSA-N 1-[(2r,3r,4r,5r)-4-hydroxy-5-(hydroxymethyl)-3-methoxyoxolan-2-yl]-3-methylpyrimidine-2,4-dione Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N(C)C(=O)C=C1 OTFGHFBGGZEXEU-PEBGCTIMSA-N 0.000 description 1
• VGHXKGWSRNEDEP-OJKLQORTSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-2,4-dioxopyrimidine-5-carboxylic acid Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)N1C(=O)NC(=O)C(C(O)=O)=C1 VGHXKGWSRNEDEP-OJKLQORTSA-N 0.000 description 1
• GZEFTKHSACGIBG-UGKPPGOTSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-propyloxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1=CC(=O)NC(=O)N1[C@]1(CCC)O[C@H](CO)[C@@H](O)[C@H]1O GZEFTKHSACGIBG-UGKPPGOTSA-N 0.000 description 1
• KYEKLQMDNZPEFU-KVTDHHQDSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)N=C1 KYEKLQMDNZPEFU-KVTDHHQDSA-N 0.000 description 1
• XIJAZGMFHRTBFY-FDDDBJFASA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-$l^{1}-selanyl-5-(methylaminomethyl)pyrimidin-4-one Chemical compound [Se]C1=NC(=O)C(CNC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XIJAZGMFHRTBFY-FDDDBJFASA-N 0.000 description 1
• UTQUILVPBZEHTK-ZOQUXTDFSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3-methylpyrimidine-2,4-dione Chemical compound O=C1N(C)C(=O)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UTQUILVPBZEHTK-ZOQUXTDFSA-N 0.000 description 1
• HXVKEKIORVUWDR-FDDDBJFASA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(methylaminomethyl)-2-sulfanylidenepyrimidin-4-one Chemical compound S=C1NC(=O)C(CNC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HXVKEKIORVUWDR-FDDDBJFASA-N 0.000 description 1
• RKSLVDIXBGWPIS-UAKXSSHOSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 RKSLVDIXBGWPIS-UAKXSSHOSA-N 0.000 description 1
• BTFXIEGOSDSOGN-KWCDMSRLSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-1,3-diazinane-2,4-dione Chemical compound O=C1NC(=O)C(C)CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 BTFXIEGOSDSOGN-KWCDMSRLSA-N 0.000 description 1
• QLOCVMVCRJOTTM-TURQNECASA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C#CC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 QLOCVMVCRJOTTM-TURQNECASA-N 0.000 description 1
• QPHRQMAYYMYWFW-FJGDRVTGSA-N 1-[(2r,3s,4r,5r)-3-fluoro-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound O[C@]1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 QPHRQMAYYMYWFW-FJGDRVTGSA-N 0.000 description 1
• XAEIGPYNMXSHAA-UHFFFAOYSA-N 1-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]propane-1-sulfonic acid Chemical compound CCC(S(O)(=O)=O)NC(CO)(CO)CO XAEIGPYNMXSHAA-UHFFFAOYSA-N 0.000 description 1
• SXUXMRMBWZCMEN-UHFFFAOYSA-N 2'-O-methyl uridine Natural products COC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 SXUXMRMBWZCMEN-UHFFFAOYSA-N 0.000 description 1
• WGNUTGFETAXDTJ-OOJXKGFFSA-N 2'-O-methylpseudouridine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O WGNUTGFETAXDTJ-OOJXKGFFSA-N 0.000 description 1
• SXUXMRMBWZCMEN-ZOQUXTDFSA-N 2'-O-methyluridine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 SXUXMRMBWZCMEN-ZOQUXTDFSA-N 0.000 description 1
• VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 description 1
• WALUVDCNGPQPOD-UHFFFAOYSA-M 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC WALUVDCNGPQPOD-UHFFFAOYSA-M 0.000 description 1
• JCNGYIGHEUKAHK-DWJKKKFUSA-N 2-Thio-1-methyl-1-deazapseudouridine Chemical compound CC1C=C(C(=O)NC1=S)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O JCNGYIGHEUKAHK-DWJKKKFUSA-N 0.000 description 1
• BVLGKOVALHRKNM-XUTVFYLZSA-N 2-Thio-1-methylpseudouridine Chemical compound CN1C=C(C(=O)NC1=S)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O BVLGKOVALHRKNM-XUTVFYLZSA-N 0.000 description 1
• CWXIOHYALLRNSZ-JWMKEVCDSA-N 2-Thiodihydropseudouridine Chemical compound C1C(C(=O)NC(=S)N1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O CWXIOHYALLRNSZ-JWMKEVCDSA-N 0.000 description 1
• VHXUHQJRMXUOST-PNHWDRBUSA-N 2-[1-[(2r,3r,4r,5r)-4-hydroxy-5-(hydroxymethyl)-3-methoxyoxolan-2-yl]-2,4-dioxopyrimidin-5-yl]acetamide Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(CC(N)=O)=C1 VHXUHQJRMXUOST-PNHWDRBUSA-N 0.000 description 1
• NUBJGTNGKODGGX-YYNOVJQHSA-N 2-[5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,4-dioxopyrimidin-1-yl]acetic acid Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CN(CC(O)=O)C(=O)NC1=O NUBJGTNGKODGGX-YYNOVJQHSA-N 0.000 description 1
• SFFCQAIBJUCFJK-UGKPPGOTSA-N 2-[[1-[(2r,3r,4r,5r)-4-hydroxy-5-(hydroxymethyl)-3-methoxyoxolan-2-yl]-2,4-dioxopyrimidin-5-yl]methylamino]acetic acid Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(CNCC(O)=O)=C1 SFFCQAIBJUCFJK-UGKPPGOTSA-N 0.000 description 1
• CTPQMQZKRWLMRA-LYTXVXJPSA-N 2-amino-4-[5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3-methyl-2,6-dioxopyrimidin-1-yl]butanoic acid Chemical compound O=C1N(CCC(N)C(O)=O)C(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 CTPQMQZKRWLMRA-LYTXVXJPSA-N 0.000 description 1
• CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
• RLZMYTZDQAVNIN-ZOQUXTDFSA-N 2-methoxy-4-thio-uridine Chemical compound COC1=NC(=S)C=CN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O RLZMYTZDQAVNIN-ZOQUXTDFSA-N 0.000 description 1
• WBVPJIKOWUQTSD-ZOQUXTDFSA-N 2-methoxyuridine Chemical compound COC1=NC(=O)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 WBVPJIKOWUQTSD-ZOQUXTDFSA-N 0.000 description 1
• JUMHLCXWYQVTLL-KVTDHHQDSA-N 2-thio-5-aza-uridine Chemical compound [C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C(=S)NC(=O)N=C1 JUMHLCXWYQVTLL-KVTDHHQDSA-N 0.000 description 1
• VRVXMIJPUBNPGH-XVFCMESISA-N 2-thio-dihydrouridine Chemical compound OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CCC(=O)NC1=S VRVXMIJPUBNPGH-XVFCMESISA-N 0.000 description 1
• GJTBSTBJLVYKAU-XVFCMESISA-N 2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C=C1 GJTBSTBJLVYKAU-XVFCMESISA-N 0.000 description 1
• YXNIEZJFCGTDKV-JANFQQFMSA-N 3-(3-amino-3-carboxypropyl)uridine Chemical compound O=C1N(CCC(N)C(O)=O)C(=O)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 YXNIEZJFCGTDKV-JANFQQFMSA-N 0.000 description 1
• NUFBIAUZAMHTSP-UHFFFAOYSA-N 3-(n-morpholino)-2-hydroxypropanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CN1CCOCC1 NUFBIAUZAMHTSP-UHFFFAOYSA-N 0.000 description 1
• DXEJZRDJXRVUPN-XUTVFYLZSA-N 3-Methylpseudouridine Chemical compound O=C1N(C)C(=O)NC=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DXEJZRDJXRVUPN-XUTVFYLZSA-N 0.000 description 1
• UTQUILVPBZEHTK-UHFFFAOYSA-N 3-Methyluridine Natural products O=C1N(C)C(=O)C=CN1C1C(O)C(O)C(CO)O1 UTQUILVPBZEHTK-UHFFFAOYSA-N 0.000 description 1
• FGFVODMBKZRMMW-XUTVFYLZSA-N 4-Methoxy-2-thiopseudouridine Chemical compound COC1=C(C=NC(=S)N1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O FGFVODMBKZRMMW-XUTVFYLZSA-N 0.000 description 1
• HOCJTJWYMOSXMU-XUTVFYLZSA-N 4-Methoxypseudouridine Chemical compound COC1=C(C=NC(=O)N1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O HOCJTJWYMOSXMU-XUTVFYLZSA-N 0.000 description 1
• ZLOIGESWDJYCTF-UHFFFAOYSA-N 4-Thiouridine Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-UHFFFAOYSA-N 0.000 description 1
• ZLOIGESWDJYCTF-XVFCMESISA-N 4-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-XVFCMESISA-N 0.000 description 1
• YHRRPHCORALGKQ-UHFFFAOYSA-N 5,2'-O-dimethyluridine Chemical compound COC1C(O)C(CO)OC1N1C(=O)NC(=O)C(C)=C1 YHRRPHCORALGKQ-UHFFFAOYSA-N 0.000 description 1
• FAWQJBLSWXIJLA-VPCXQMTMSA-N 5-(carboxymethyl)uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(CC(O)=O)=C1 FAWQJBLSWXIJLA-VPCXQMTMSA-N 0.000 description 1
• MMUBPEFMCTVKTR-IBNKKVAHSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-methyloxolan-2-yl]-1h-pyrimidine-2,4-dione Chemical compound C=1NC(=O)NC(=O)C=1[C@]1(C)O[C@H](CO)[C@@H](O)[C@H]1O MMUBPEFMCTVKTR-IBNKKVAHSA-N 0.000 description 1
• AMMRPAYSYYGRKP-BGZDPUMWSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1-ethylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)N(CC)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 AMMRPAYSYYGRKP-BGZDPUMWSA-N 0.000 description 1
• ITGWEVGJUSMCEA-KYXWUPHJSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1-prop-1-ynylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)N(C#CC)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ITGWEVGJUSMCEA-KYXWUPHJSA-N 0.000 description 1
• DDHOXEOVAJVODV-GBNDHIKLSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=S)NC1=O DDHOXEOVAJVODV-GBNDHIKLSA-N 0.000 description 1
• BNAWMJKJLNJZFU-GBNDHIKLSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-sulfanylidene-1h-pyrimidin-2-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=S BNAWMJKJLNJZFU-GBNDHIKLSA-N 0.000 description 1
• LOEDKMLIGFMQKR-JXOAFFINSA-N 5-aminomethyl-2-thiouridine Chemical compound S=C1NC(=O)C(CN)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 LOEDKMLIGFMQKR-JXOAFFINSA-N 0.000 description 1
• QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
• AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 description 1
• HLZXTFWTDIBXDF-PNHWDRBUSA-N 5-methoxycarbonylmethyl-2-thiouridine Chemical compound S=C1NC(=O)C(CC(=O)OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HLZXTFWTDIBXDF-PNHWDRBUSA-N 0.000 description 1
• YIZYCHKPHCPKHZ-PNHWDRBUSA-N 5-methoxycarbonylmethyluridine Chemical compound O=C1NC(=O)C(CC(=O)OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 YIZYCHKPHCPKHZ-PNHWDRBUSA-N 0.000 description 1
• SNNBPMAXGYBMHM-JXOAFFINSA-N 5-methyl-2-thiouridine Chemical compound S=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 SNNBPMAXGYBMHM-JXOAFFINSA-N 0.000 description 1
• HXVKEKIORVUWDR-UHFFFAOYSA-N 5-methylaminomethyl-2-thiouridine Natural products S=C1NC(=O)C(CNC)=CN1C1C(O)C(O)C(CO)O1 HXVKEKIORVUWDR-UHFFFAOYSA-N 0.000 description 1
• ZXQHKBUIXRFZBV-FDDDBJFASA-N 5-methylaminomethyluridine Chemical compound O=C1NC(=O)C(CNC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZXQHKBUIXRFZBV-FDDDBJFASA-N 0.000 description 1
• WYXSYVWAUAUWLD-SHUUEZRQSA-N 6-azauridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-SHUUEZRQSA-N 0.000 description 1
• 206010000117 Abnormal behaviour Diseases 0.000 description 1
• 206010001367 Adrenal insufficiency Diseases 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• 102000002572 Alpha-Globulins Human genes 0.000 description 1
• 108010068307 Alpha-Globulins Proteins 0.000 description 1
• 206010002091 Anaesthesia Diseases 0.000 description 1
• 101710145634 Antigen 1 Proteins 0.000 description 1
• 241000180579 Arca Species 0.000 description 1
• 108700016232 Arg(2)-Sar(4)- dermorphin (1-4) Proteins 0.000 description 1
• 108091008875 B cell receptors Proteins 0.000 description 1
• 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 206010005003 Bladder cancer Diseases 0.000 description 1
• 206010005949 Bone cancer Diseases 0.000 description 1
• 208000018084 Bone neoplasm Diseases 0.000 description 1
• 241000588832 Bordetella pertussis Species 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 208000014644 Brain disease Diseases 0.000 description 1
• XYCOFVHHXFNAGU-DNRKLUKYSA-N C(=O)=COC=CC=1C(NC(N([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C1)=O)=O Chemical compound C(=O)=COC=CC=1C(NC(N([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C1)=O)=O XYCOFVHHXFNAGU-DNRKLUKYSA-N 0.000 description 1
• KZNMUKLEOMANLY-HKUMRIAESA-N C(C=C(C)C)NCC=1C(NC(N([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C1)=S)=O Chemical compound C(C=C(C)C)NCC=1C(NC(N([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C1)=S)=O KZNMUKLEOMANLY-HKUMRIAESA-N 0.000 description 1
• LUZQNJKKCXNVPW-RGCMKSIDSA-N C(C=C(C)C)NCC=1C(NC(N([C@H]2[C@H](OC)[C@H](O)[C@@H](CO)O2)C1)=O)=O Chemical compound C(C=C(C)C)NCC=1C(NC(N([C@H]2[C@H](OC)[C@H](O)[C@@H](CO)O2)C1)=O)=O LUZQNJKKCXNVPW-RGCMKSIDSA-N 0.000 description 1
• 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
• 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
• 238000011740 C57BL/6 mouse Methods 0.000 description 1
• KENUMLQSABMMIG-UHFFFAOYSA-N CCCCCCCCCCCCCCOCC(CCN(C)CCO)OCCCCCCCCCCCCCC Chemical compound CCCCCCCCCCCCCCOCC(CCN(C)CCO)OCCCCCCCCCCCCCC KENUMLQSABMMIG-UHFFFAOYSA-N 0.000 description 1
• 101150013553 CD40 gene Proteins 0.000 description 1
• 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
• 108091058556 CTAG1B Proteins 0.000 description 1
• 101150090257 CTAG1B gene Proteins 0.000 description 1
• 108091058559 CXorf61 Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 102000000844 Cell Surface Receptors Human genes 0.000 description 1
• 108010001857 Cell Surface Receptors Proteins 0.000 description 1
• 206010051290 Central nervous system lesion Diseases 0.000 description 1
• 206010009944 Colon cancer Diseases 0.000 description 1
• 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 1
• 229930183912 Cytidylic acid Natural products 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• 102000053602 DNA Human genes 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• YKWUPFSEFXSGRT-JWMKEVCDSA-N Dihydropseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1C(=O)NC(=O)NC1 YKWUPFSEFXSGRT-JWMKEVCDSA-N 0.000 description 1
• ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical group [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
• 108010067770 Endopeptidase K Proteins 0.000 description 1
• 102100039328 Endoplasmin Human genes 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 108091092584 GDNA Proteins 0.000 description 1
• 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
• 206010018338 Glioma Diseases 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
• 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 description 1
• 108010093013 HLA-DR1 Antigen Proteins 0.000 description 1
• 108010039343 HLA-DRB1 Chains Proteins 0.000 description 1
• 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
• 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
• 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
• 101000812663 Homo sapiens Endoplasmin Proteins 0.000 description 1
• 101000986086 Homo sapiens HLA class I histocompatibility antigen, A alpha chain Proteins 0.000 description 1
• 101001009007 Homo sapiens Hemoglobin subunit alpha Proteins 0.000 description 1
• 101001005722 Homo sapiens Melanoma-associated antigen 6 Proteins 0.000 description 1
• 101001114056 Homo sapiens P antigen family member 2 Proteins 0.000 description 1
• 101001005721 Homo sapiens Putative melanoma-associated antigen 5P Proteins 0.000 description 1
• 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 1
• 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
• 102000008100 Human Serum Albumin Human genes 0.000 description 1
• 108091006905 Human Serum Albumin Proteins 0.000 description 1
• 206010020850 Hyperthyroidism Diseases 0.000 description 1
• 206010062767 Hypophysitis Diseases 0.000 description 1
• 206010021067 Hypopituitarism Diseases 0.000 description 1
• 108060003951 Immunoglobulin Proteins 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 102100034343 Integrase Human genes 0.000 description 1
• 206010022524 Intentional self-injury Diseases 0.000 description 1
• 102000008070 Interferon-gamma Human genes 0.000 description 1
• 108010002352 Interleukin-1 Proteins 0.000 description 1
• 108090000174 Interleukin-10 Proteins 0.000 description 1
• 108010065805 Interleukin-12 Proteins 0.000 description 1
• 108010002350 Interleukin-2 Proteins 0.000 description 1
• 108010002386 Interleukin-3 Proteins 0.000 description 1
• 108090000978 Interleukin-4 Proteins 0.000 description 1
• 108010002616 Interleukin-5 Proteins 0.000 description 1
• 108090001005 Interleukin-6 Proteins 0.000 description 1
• 108010002586 Interleukin-7 Proteins 0.000 description 1
• 108090001007 Interleukin-8 Proteins 0.000 description 1
• 108010002335 Interleukin-9 Proteins 0.000 description 1
• 206010051925 Intestinal adenocarcinoma Diseases 0.000 description 1
• 206010061252 Intraocular melanoma Diseases 0.000 description 1
• PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 108010028921 Lipopeptides Proteins 0.000 description 1
• 108010074338 Lymphokines Proteins 0.000 description 1
• 102000008072 Lymphokines Human genes 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 108050008953 Melanoma-associated antigen Proteins 0.000 description 1
• 102100025075 Melanoma-associated antigen 6 Human genes 0.000 description 1
• 206010051696 Metastases to meninges Diseases 0.000 description 1
• 108700005084 Multigene Family Proteins 0.000 description 1
• 208000034578 Multiple myelomas Diseases 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
• 108010084333 N-palmitoyl-S-(2,3-bis(palmitoyloxy)propyl)cysteinyl-seryl-lysyl-lysyl-lysyl-lysine Proteins 0.000 description 1
• 206010060860 Neurological symptom Diseases 0.000 description 1
• 206010067482 No adverse event Diseases 0.000 description 1
• 108091005461 Nucleic proteins Proteins 0.000 description 1
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
• 108091034117 Oligonucleotide Proteins 0.000 description 1
• 108010038807 Oligopeptides Proteins 0.000 description 1
• 102000015636 Oligopeptides Human genes 0.000 description 1
• 208000001388 Opportunistic Infections Diseases 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 206010033128 Ovarian cancer Diseases 0.000 description 1
• 206010061535 Ovarian neoplasm Diseases 0.000 description 1
• 102100023220 P antigen family member 2 Human genes 0.000 description 1
• 239000007990 PIPES buffer Substances 0.000 description 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
• 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 108010033276 Peptide Fragments Proteins 0.000 description 1
• 102000007079 Peptide Fragments Human genes 0.000 description 1
• 241000009328 Perro Species 0.000 description 1
• 108010081690 Pertussis Toxin Proteins 0.000 description 1
• 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
• 241000183024 Populus tremula Species 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 238000010806 PrimeScriptTM RT Reagent kit Methods 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 108091008109 Pseudogenes Proteins 0.000 description 1
• 102000057361 Pseudogenes Human genes 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• 102100025078 Putative melanoma-associated antigen 5P Human genes 0.000 description 1
• 238000002123 RNA extraction Methods 0.000 description 1
• 238000010802 RNA extraction kit Methods 0.000 description 1
• 108010065868 RNA polymerase SP6 Proteins 0.000 description 1
• 239000013614 RNA sample Substances 0.000 description 1
• 102100038823 RNA-binding protein 45 Human genes 0.000 description 1
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 208000015634 Rectal Neoplasms Diseases 0.000 description 1
• 206010038389 Renal cancer Diseases 0.000 description 1
• 208000006265 Renal cell carcinoma Diseases 0.000 description 1
• 108091028664 Ribonucleotide Proteins 0.000 description 1
• 239000008156 Ringer's lactate solution Substances 0.000 description 1
• 208000005560 Self Mutilation Diseases 0.000 description 1
• 208000032023 Signs and Symptoms Diseases 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
• 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
• 206010041549 Spinal cord compression Diseases 0.000 description 1
• 208000020307 Spinal disease Diseases 0.000 description 1
• 229930182558 Sterol Natural products 0.000 description 1
• 208000005718 Stomach Neoplasms Diseases 0.000 description 1
• 241000282898 Sus scrofa Species 0.000 description 1
• UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
• 108091008874 T cell receptors Proteins 0.000 description 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
• 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
• 101710137500 T7 RNA polymerase Proteins 0.000 description 1
• 102100040296 TATA-box-binding protein Human genes 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• XOAAWQZATWQOTB-UHFFFAOYSA-N Taurine Natural products NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 1
• 108091036066 Three prime untranslated region Proteins 0.000 description 1
• 208000024770 Thyroid neoplasm Diseases 0.000 description 1
• 102000000591 Tight Junction Proteins Human genes 0.000 description 1
• 108010002321 Tight Junction Proteins Proteins 0.000 description 1
• HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
• 239000007997 Tricine buffer Substances 0.000 description 1
• DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
• 208000034953 Twin anemia-polycythemia sequence Diseases 0.000 description 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
• 201000005969 Uveal melanoma Diseases 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 206010047642 Vitiligo Diseases 0.000 description 1
• 206010052428 Wound Diseases 0.000 description 1
• 210000001766 X chromosome Anatomy 0.000 description 1
• YXNIEZJFCGTDKV-UHFFFAOYSA-N X-Nucleosid Natural products O=C1N(CCC(N)C(O)=O)C(=O)C=CN1C1C(O)C(O)C(CO)O1 YXNIEZJFCGTDKV-UHFFFAOYSA-N 0.000 description 1
• 241001441550 Zeiformes Species 0.000 description 1
• RBPWQIKZHBYIEY-PXCYNBOKSA-N [(2r)-2,3-bis[(z)-octadec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC RBPWQIKZHBYIEY-PXCYNBOKSA-N 0.000 description 1
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
• CKUAXEQHGKSLHN-UHFFFAOYSA-N [C].[N] Chemical compound [C].[N] CKUAXEQHGKSLHN-UHFFFAOYSA-N 0.000 description 1
• VEWJOCYCKIZKKV-GBNDHIKLSA-N [[(2r,3s,4r,5s)-5-(2,4-dioxo-1h-pyrimidin-5-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1C1=CNC(=O)NC1=O VEWJOCYCKIZKKV-GBNDHIKLSA-N 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 239000008186 active pharmaceutical agent Substances 0.000 description 1
• 125000002252 acyl group Chemical group 0.000 description 1
• 229960005305 adenosine Drugs 0.000 description 1
• 238000009098 adjuvant therapy Methods 0.000 description 1
• 230000001919 adrenal effect Effects 0.000 description 1
• 210000004100 adrenal gland Anatomy 0.000 description 1
• 201000005188 adrenal gland cancer Diseases 0.000 description 1
• 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
• 208000017515 adrenocortical insufficiency Diseases 0.000 description 1
• HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
• 229940037003 alum Drugs 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 230000001668 ameliorated effect Effects 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 230000037005 anaesthesia Effects 0.000 description 1
• 239000012491 analyte Substances 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 230000002424 anti-apoptotic effect Effects 0.000 description 1
• 230000001093 anti-cancer Effects 0.000 description 1
• 230000003466 anti-cipated effect Effects 0.000 description 1
• 230000003127 anti-melanomic effect Effects 0.000 description 1
• 230000000259 anti-tumor effect Effects 0.000 description 1
• 230000005875 antibody response Effects 0.000 description 1
• 239000012062 aqueous buffer Substances 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• 238000000889 atomisation Methods 0.000 description 1
• 238000013475 authorization Methods 0.000 description 1
• 238000011888 autopsy Methods 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
• 210000004082 barrier epithelial cell Anatomy 0.000 description 1
• 230000006399 behavior Effects 0.000 description 1
• 229960000686 benzalkonium chloride Drugs 0.000 description 1
• CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• HMFHBZSHGGEWLO-TXICZTDVSA-N beta-D-ribose Chemical group OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-TXICZTDVSA-N 0.000 description 1
• 239000007998 bicine buffer Substances 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 239000000090 biomarker Substances 0.000 description 1
• 210000002459 blastocyst Anatomy 0.000 description 1
• 201000000053 blastoma Diseases 0.000 description 1
• 230000036760 body temperature Effects 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
• 239000004327 boric acid Substances 0.000 description 1
• 210000004900 c-terminal fragment Anatomy 0.000 description 1
• 239000011575 calcium Chemical class 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
• 230000005773 cancer-related death Effects 0.000 description 1
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 231100000504 carcinogenesis Toxicity 0.000 description 1
• 238000006555 catalytic reaction Methods 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000032823 cell division Effects 0.000 description 1
• 210000003855 cell nucleus Anatomy 0.000 description 1
• 210000004671 cell-free system Anatomy 0.000 description 1
• 230000003399 chemotactic effect Effects 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 238000011260 co-administration Methods 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 238000004891 communication Methods 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 238000010668 complexation reaction Methods 0.000 description 1
• 238000004590 computer program Methods 0.000 description 1
• 238000011970 concomitant therapy Methods 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 208000030381 cutaneous melanoma Diseases 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 description 1
• IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 description 1
• 230000016396 cytokine production Effects 0.000 description 1
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 238000002784 cytotoxicity assay Methods 0.000 description 1
• 231100000263 cytotoxicity test Toxicity 0.000 description 1
• GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 238000007405 data analysis Methods 0.000 description 1
• 229960000958 deferoxamine Drugs 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 239000005547 deoxyribonucleotide Substances 0.000 description 1
• 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• UMGXUWVIJIQANV-UHFFFAOYSA-M didecyl(dimethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC UMGXUWVIJIQANV-UHFFFAOYSA-M 0.000 description 1
• KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
• NAPSCFZYZVSQHF-UHFFFAOYSA-N dimantine Chemical compound CCCCCCCCCCCCCCCCCCN(C)C NAPSCFZYZVSQHF-UHFFFAOYSA-N 0.000 description 1
• PFKRTWCFCOUBHS-UHFFFAOYSA-N dimethyl(octadecyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[NH+](C)C PFKRTWCFCOUBHS-UHFFFAOYSA-N 0.000 description 1
• 235000019797 dipotassium phosphate Nutrition 0.000 description 1
• 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
• 150000002016 disaccharides Chemical class 0.000 description 1
• XDDWTKNHOVUZBU-UHFFFAOYSA-L disodium;methanethioate Chemical class [Na+].[Na+].[O-]C([S-])=S XDDWTKNHOVUZBU-UHFFFAOYSA-L 0.000 description 1
• 229940088679 drug related substance Drugs 0.000 description 1
• 238000001035 drying Methods 0.000 description 1
• 210000003162 effector t lymphocyte Anatomy 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 230000013020 embryo development Effects 0.000 description 1
• 201000008184 embryoma Diseases 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 210000000750 endocrine system Anatomy 0.000 description 1
• 210000001339 epidermal cell Anatomy 0.000 description 1
• 230000004890 epithelial barrier function Effects 0.000 description 1
• 210000003386 epithelial cell of thymus gland Anatomy 0.000 description 1
• 210000003743 erythrocyte Anatomy 0.000 description 1
• 201000004101 esophageal cancer Diseases 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 210000003527 eukaryotic cell Anatomy 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 238000013100 final test Methods 0.000 description 1
• 238000009093 first-line therapy Methods 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 239000012595 freezing medium Substances 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 206010017758 gastric cancer Diseases 0.000 description 1
• 238000010353 genetic engineering Methods 0.000 description 1
• 210000004602 germ cell Anatomy 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 235000004554 glutamine Nutrition 0.000 description 1
• 150000004676 glycans Chemical class 0.000 description 1
• 150000002338 glycosides Chemical group 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 239000004226 guanylic acid Substances 0.000 description 1
• 230000003394 haemopoietic effect Effects 0.000 description 1
• 201000010536 head and neck cancer Diseases 0.000 description 1
• 208000014829 head and neck neoplasm Diseases 0.000 description 1
• 230000003862 health status Effects 0.000 description 1
• 201000005787 hematologic cancer Diseases 0.000 description 1
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 238000002657 hormone replacement therapy Methods 0.000 description 1
• 230000028996 humoral immune response Effects 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 230000003301 hydrolyzing effect Effects 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
• 208000003532 hypothyroidism Diseases 0.000 description 1
• 230000002989 hypothyroidism Effects 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 description 1
• 238000011502 immune monitoring Methods 0.000 description 1
• 102000018358 immunoglobulin Human genes 0.000 description 1
• 238000011532 immunohistochemical staining Methods 0.000 description 1
• 238000003364 immunohistochemistry Methods 0.000 description 1
• 238000013388 immunohistochemistry analysis Methods 0.000 description 1
• 239000003547 immunosorbent Substances 0.000 description 1
• 230000003308 immunostimulating effect Effects 0.000 description 1
• 238000000126 in silico method Methods 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 229960003130 interferon gamma Drugs 0.000 description 1
• 201000002313 intestinal cancer Diseases 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 229960002725 isoflurane Drugs 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 239000000644 isotonic solution Substances 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 230000021633 leukocyte mediated immunity Effects 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 201000007270 liver cancer Diseases 0.000 description 1
• 208000014018 liver neoplasm Diseases 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 210000004324 lymphatic system Anatomy 0.000 description 1
• 210000005210 lymphoid organ Anatomy 0.000 description 1
• 239000012139 lysis buffer Substances 0.000 description 1
• 229910001629 magnesium chloride Inorganic materials 0.000 description 1
• GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
• 239000004137 magnesium phosphate Substances 0.000 description 1
• 229960002261 magnesium phosphate Drugs 0.000 description 1
• 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
• 235000010994 magnesium phosphates Nutrition 0.000 description 1
• 238000002595 magnetic resonance imaging Methods 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
• 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
• 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
• 230000000873 masking effect Effects 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• HLZXTFWTDIBXDF-UHFFFAOYSA-N mcm5sU Natural products COC(=O)Cc1cn(C2OC(CO)C(O)C2O)c(=S)[nH]c1=O HLZXTFWTDIBXDF-UHFFFAOYSA-N 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 206010027191 meningioma Diseases 0.000 description 1
• 230000003340 mental effect Effects 0.000 description 1
• 229910021645 metal ion Inorganic materials 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• XOTXNXXJZCFUOA-UGKPPGOTSA-N methyl 2-[1-[(2r,3r,4r,5r)-4-hydroxy-5-(hydroxymethyl)-3-methoxyoxolan-2-yl]-2,4-dioxopyrimidin-5-yl]acetate Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(CC(=O)OC)=C1 XOTXNXXJZCFUOA-UGKPPGOTSA-N 0.000 description 1
• WZRYXYRWFAPPBJ-PNHWDRBUSA-N methyl uridin-5-yloxyacetate Chemical compound O=C1NC(=O)C(OCC(=O)OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 WZRYXYRWFAPPBJ-PNHWDRBUSA-N 0.000 description 1
• 239000013586 microbial product Substances 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 235000010755 mineral Nutrition 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
• 235000019796 monopotassium phosphate Nutrition 0.000 description 1
• 150000002772 monosaccharides Chemical class 0.000 description 1
• 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
• 210000004898 n-terminal fragment Anatomy 0.000 description 1
• 150000002790 naphthalenes Chemical class 0.000 description 1
• 210000002241 neurite Anatomy 0.000 description 1
• 201000002120 neuroendocrine carcinoma Diseases 0.000 description 1
• 210000004498 neuroglial cell Anatomy 0.000 description 1
• MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 1
• 231100000956 nontoxicity Toxicity 0.000 description 1
• 238000010606 normalization Methods 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 230000030648 nucleus localization Effects 0.000 description 1
• 201000002575 ocular melanoma Diseases 0.000 description 1
• 229920001542 oligosaccharide Polymers 0.000 description 1
• 150000002482 oligosaccharides Chemical class 0.000 description 1
• 239000002357 osmotic agent Substances 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 230000001590 oxidative effect Effects 0.000 description 1
• 230000000242 pagocytic effect Effects 0.000 description 1
• 230000036407 pain Effects 0.000 description 1
• 201000002528 pancreatic cancer Diseases 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 229960001639 penicillamine Drugs 0.000 description 1
• 150000002972 pentoses Chemical group 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 230000035699 permeability Effects 0.000 description 1
• 230000002688 persistence Effects 0.000 description 1
• 239000008024 pharmaceutical diluent Substances 0.000 description 1
• PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 210000003635 pituitary gland Anatomy 0.000 description 1
• 210000004180 plasmocyte Anatomy 0.000 description 1
• 229920001515 polyalkylene glycol Polymers 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 102000040430 polynucleotide Human genes 0.000 description 1
• 108091033319 polynucleotide Proteins 0.000 description 1
• 239000002157 polynucleotide Substances 0.000 description 1
• 229920001451 polypropylene glycol Polymers 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 239000011148 porous material Substances 0.000 description 1
• 239000011736 potassium bicarbonate Substances 0.000 description 1
• 235000015497 potassium bicarbonate Nutrition 0.000 description 1
• 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
• 239000001103 potassium chloride Substances 0.000 description 1
• 235000011164 potassium chloride Nutrition 0.000 description 1
• TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
• OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
• 229910052939 potassium sulfate Inorganic materials 0.000 description 1
• 235000011151 potassium sulphates Nutrition 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 229960005205 prednisolone Drugs 0.000 description 1
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
• 229960004618 prednisone Drugs 0.000 description 1
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 201000001722 pulmonary large cell neuroendocrine carcinoma Diseases 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 108020003175 receptors Proteins 0.000 description 1
• 102000005962 receptors Human genes 0.000 description 1
• 206010038038 rectal cancer Diseases 0.000 description 1
• 201000001275 rectum cancer Diseases 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 201000010174 renal carcinoma Diseases 0.000 description 1
• 201000007444 renal pelvis carcinoma Diseases 0.000 description 1
• 230000001850 reproductive effect Effects 0.000 description 1
• 201000011453 reproductive organ cancer Diseases 0.000 description 1
• 208000015608 reproductive system cancer Diseases 0.000 description 1
• 230000029058 respiratory gaseous exchange Effects 0.000 description 1
• 210000002345 respiratory system Anatomy 0.000 description 1
• 238000013215 result calculation Methods 0.000 description 1
• 102000003702 retinoic acid receptors Human genes 0.000 description 1
• 108090000064 retinoic acid receptors Proteins 0.000 description 1
• 239000002336 ribonucleotide Substances 0.000 description 1
• 238000010845 search algorithm Methods 0.000 description 1
• 238000012764 semi-quantitative analysis Methods 0.000 description 1
• 150000003355 serines Chemical class 0.000 description 1
• 230000001568 sexual effect Effects 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 201000003708 skin melanoma Diseases 0.000 description 1
• 229910052938 sodium sulfate Inorganic materials 0.000 description 1
• 235000011152 sodium sulphate Nutrition 0.000 description 1
• 239000007790 solid phase Substances 0.000 description 1
• 238000007711 solidification Methods 0.000 description 1
• 230000008023 solidification Effects 0.000 description 1
• 210000001082 somatic cell Anatomy 0.000 description 1
• 229940063675 spermine Drugs 0.000 description 1
• 208000037959 spinal tumor Diseases 0.000 description 1
• 238000010911 splenectomy Methods 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 150000003432 sterols Chemical class 0.000 description 1
• 235000003702 sterols Nutrition 0.000 description 1
• 238000003756 stirring Methods 0.000 description 1
• 239000011550 stock solution Substances 0.000 description 1
• 201000011549 stomach cancer Diseases 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• ACTRVOBWPAIOHC-XIXRPRMCSA-N succimer Chemical compound OC(=O)[C@@H](S)[C@@H](S)C(O)=O ACTRVOBWPAIOHC-XIXRPRMCSA-N 0.000 description 1
• 229960005346 succimer Drugs 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 239000008399 tap water Substances 0.000 description 1
• 235000020679 tap water Nutrition 0.000 description 1
• 238000002626 targeted therapy Methods 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 229960003080 taurine Drugs 0.000 description 1
• 238000012956 testing procedure Methods 0.000 description 1
• UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• 239000012749 thinning agent Substances 0.000 description 1
• 201000002510 thyroid cancer Diseases 0.000 description 1
• 210000001578 tight junction Anatomy 0.000 description 1
• 239000012929 tonicity agent Substances 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 231100000155 toxicity by organ Toxicity 0.000 description 1
• 230000007675 toxicity by organ Effects 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 229960001124 trientine Drugs 0.000 description 1
• 150000004043 trisaccharides Chemical class 0.000 description 1
• 230000005748 tumor development Effects 0.000 description 1
• 230000004222 uncontrolled growth Effects 0.000 description 1
• RVCNQQGZJWVLIP-VPCXQMTMSA-N uridin-5-yloxyacetic acid Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(OCC(O)=O)=C1 RVCNQQGZJWVLIP-VPCXQMTMSA-N 0.000 description 1
• YIZYCHKPHCPKHZ-UHFFFAOYSA-N uridine-5-acetic acid methyl ester Natural products COC(=O)Cc1cn(C2OC(CO)C(O)C2O)c(=O)[nH]c1=O YIZYCHKPHCPKHZ-UHFFFAOYSA-N 0.000 description 1
• 201000005112 urinary bladder cancer Diseases 0.000 description 1
• 210000003556 vascular endothelial cell Anatomy 0.000 description 1
• 230000007332 vesicle formation Effects 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 230000004580 weight loss Effects 0.000 description 1
• 239000002023 wood Substances 0.000 description 1